78results about How to "Selective inhibition" patented technology

A semiconductor device includes memory blocks MB1 and MB2 and redundancy determination circuit 25 that can enter a normal operation mode that accesses either memory block MB1 or memory block MB2 and a refresh mode that simultaneously accesses both memory block MB1 and memory block MB2. In response to normal memory cell NMC that belongs to at least one of memory blocks MB1 and MB2 being replaced by redundant memory cell RMC in the refresh mode, redundancy determination circuit 25 deactivates normal cell area NCA to which normal memory cell NMC that is a source of replacement belongs, and activates redundant cell area RCA to which redundant memory cell RMC that is to be replaced belongs and normal cell area NCA to which normal memory cell NMC that is not being replaced belongs.

Controlling access to a control register of a microprocessor. A method of controlling access to a control register such as CR3, for example, of a processor having a normal execution mode and a secure execution mode may include storing address translation table information in the control register, allowing a software invoked write access to modify the address translation table information during the normal execution mode and selectively inhibiting the software invoked write during the secure execution mode.

The invention discloses a nitrogen-containing fused heterocycle compound shown by a formula I, a pharmaceutically acceptable salt thereof, or enantiomers, diastereoisomers, tautomers, solvates, metabolic precursors or prodrugs of the nitrogen-containing fused heterocycle compound and the pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the nitrogen-containing fused heterocycle compound and an application of the nitrogen-containing fused heterocycle compound. The nitrogen-containing fused heterocycle compound disclosed by the invention has relatively good antitumor activity.

In one embodiment, a processor comprises a fetch unit and a pick unit. The fetch unit is configured to fetch instructions for execution by the processor. The pick unit is configured to schedule instructions fetched by the fetch unit for execution in the processor. The pick unit is configured to inhibit scheduling a delayed control transfer instruction (DCTI) until a delay slot instruction of the DCTI is available for scheduling. For example, in some embodiments, the pick unit may inhibit scheduling until the delay slot instruction is written to an instruction buffer, until the delay slot instruction is fetched, etc.

The invention discloses a novel 2-hydroxyl chalcone compound (I), as well as pharmacy acceptable salt, preparation method, medical composition, and purpose thereof in preparing medicines for treating and / or preventing neurodegenerative diseases including but not limited to vascular dementia, Alzheimer's diseases, Parkinson's diseases, Huntington's diseases, dementia relevant to HIV, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, glaucoma and the like (As shown in the description.).

The invention provides a Fischer-Tropsch synthetic catalyst for preparing low-carbon olefin by utilizing synthetic gas, a modified molecular sieve carrier and a preparation method. The Fischer-Tropsch synthetic catalyst comprises the components, namely a molecular sieve carrier and an active component, wherein the molecular sieve is a silicon-aluminium molecular sieve and / or high-silicon molecular sieve carrier modified by cerate and / or praseodymium salt, the active component takes Fe as a main component and also comprises active components, namely Mn and Cu, and an alkaline auxiliary, and the modified molecular sieve accounts for 40-80wt%; mass percent of the cerate and / or praseodymium salt on the modified molecular sieve is 1-20% of the molecular sieve; the cerate and / or praseodymium salt modified molecular sieve carrier is a cerium and / or praseodymium modified molecular sieve formed by treating a silicon-aluminium molecular sieve and / or high-silicon molecular sieve with an acid solution to obtain a hydrogen type molecular sieve, steeping the hydrogen type molecular sieve in a cerate and / or praseodymium salt solution and then drying and roasting; the cerate and / or praseodymium salt modified molecular sieve is steeped in a saline solution of the active component; and then drying and roasting are carried out, so that the Fischer-Tropsch synthetic catalyst for preparing the low carbon olefin by utilizing the synthetic gas is obtained.

The invention discloses a method for selecting scheelite at normal temperature. The method comprises the following steps: (1) pulping: a raw ore is milled and classified to prepare pulp with a concentration of 30-35%; the pulp is injected in a flotation machine; and the pH of the pulp is adjusted within 7-9; (2) roughing: a water glass and sodium humate combined inhibiting agent is adopted to inhibit a calcium-contained gangue mineral; and a sodium oleate and benzohydroxamic acid combined capturing agent is added for roughing and scavenging to obtain a scheelite concentrate; (3) the concentration of the scheelite concentrate is condensed to 60%; and the water glass and sodium humate combined inhibiting agent is added for strongly stirring by above 30 m under the effect of a normal-temperature magnetic field to dilute to the mass concentration of 30%; and (4) six times of blank selection are performed for the scheelite concentrate treated in the step (3) to obtain the scheelite concentrate.

The invention relates to a gamma methyl ethyl ketone acid derivative represented by general formula (I), and contains gamma-aryl-alpha-amido-beta, its preparing process, pharmaceutical compositions containing them and use as medicament, in particular as medicament for treating osteoarthritis and tumor.

The invention discloses a heterarylation compound and application thereof to drugs, and particularly discloses a heterarylation compound or stereoisomers, geometric isomers, tautomers, nitrogen oxide, hydrate, solvates, metabolites, pharmaceutically acceptable salt or pro-drugs of the heterarylation compound and a drug composition with the heterarylation compound. The invention further discloses application of the compound or the drug composition to drug preparation. The drugs can be used for treating autoimmune diseases or proliferative diseases.

The invention belongs to ethylene preparation through direct hydrogenation conversion of carbon monoxide, and particularly relates to a base-modified catalyst and a method for preparing ethylene through a hydrogenating reaction of carbon monoxide. According to the method, mixed gas of carbon monoxide and hydrogen is adopted as a reaction raw material, a conversion reaction is performed on a fixedbed or a mobile bed, and a catalyst which is a composite catalyst is obtained by compounding a component A and a component B together through mechanical mixing; and active components of the componentA are metal oxide, and the component B is an organic alkali-modified molecular sieve with an MOR structure; the weight ratio of the active components of the component A to the component B is 0.1-20, preferably 0.3-8, and the reaction process has a high product yield and selectivity; and the selectivity to C2-C3 olefin is as high as 86-92%, hydrocarbon products containing four carbon atoms or aboveare less than 7%, and the selectivity to a by-product methane is extremely low and lower than 5%; and the selectivity and space-time yield of ethylene are obviously improved, and the selectivity reaches 75-85%, and the method has a good application prospect.

The invention provides a novel use of a ganoderic acid component with a structure shown in the general formula I as a 11 beta-HSD inhibitor. The ganoderic acid component as a 11 beta-hydroxysteroid dehydrogenase inhibitor with a novel structure has a certain selective inhibition effect on 11 beta-HSD1 and can be used for preparation of drugs for adjusting lipid metabolism and treating diabetes, adiposis and cardiovascular diseases.

The present invention relates to a compound according to Formula (I): A-(L-Y)p, wherein A comprises at least one substantially cell-membrane impermeable pendant group; L comprises any suitable linker and / or spacer group; Y comprises at least one arsenoxide or arsenoxide equivalent; p is an integer from 1 to 10; and the sum total of carbon atoms in A and L together, is greater than 6.

The invention discloses a feed additive capable of improving anti-stress and immunity of ruminants and a preparation method thereof. The feed additive capable of improving the anti-stress capability and immunity of ruminants is prepared from the following raw materials: bacillus subtilis powder, lactobacillus plantarum powder, saccharomycete powder, catechuic acid, xylooligosaccharide, calcium fatty acids, chromium nicotinate, medical stone, vitamin C, vitamin B1, nicotinic acid, pine pollen, tricalcium phosphate, manganese sulfate, soy isoflavone, berberine, soya bean meal, versioolor swallowwort root, herba ephedra, futokadsura stem, herba potentillae chinensis, ford manglietia fruit, ciliate desert-grass, ajuga decumbens, tangerine leaves, cow soapwortseed and table salt. The feed additive capable of improving the anti-stress capability and immunity of ruminants contains multiplex vitamins, trace elements and Chinese medicinal herb ingredients, and all the ingredients achieve a synergistic effect, so that the intestinal micro-ecological environments of ruminants can be effectively improved, the quantity of pathogens is reduced, stress reaction is reduced to a great extent, the immunity is improved and thus the disease incidence of ruminants.

Provided is a printed circuit board realizing selective inhibition of electromagnetic noise and enabling high-density arrangement of differential transmission lines without increasing cost. The printed circuit board includes a pair of strip conductors (first layer), a first resonance conductor plate, a ground conductive layer (together with a second layer) including an opening portion, a second resonance conductor plate (third layer), a third resonance conductor plate (fourth layer), first via holes connecting the first and second resonance conductor plates, a second via hole connecting the second and third resonance conductor plates, and third via holes connecting the third resonance conductor plate and the ground conductive layer, wherein a polygon obtained by sequentially connecting centers of the adjacent third via holes overlaps so as to include the first resonance conductor plate, and center-to-center distance between the adjacent third via holes is 0.5 wavelength or less at frequency corresponding to the bit rate.

The invention belongs to the technical field of medicinal chemistry and discloses a N-(1,2,3,4-tetrahydroisoquinolinyl)-feruloylagmatine-O-alkylamine compound (I) and pharmaceutically acceptable salt, and a preparation method and application thereof. The structure is as shown in a formula I. The compound (I) provided by the invention has high butyrylcholine esterase inhibiting activity, anti-oxidation activity and Abeta1-42 aggregation inhibiting activity, and has remarkable neuroprotective function on PC12 cell injury induced by hydrogen peroxide, which indicates that the compound is a multi-target-point inhibitor. The compound further shows a good effect of treating alzheimer disease in in-vivo experiments, and has low toxicity and a good clinical application prospect.

The invention discloses a catalyst for co-production of low carbon alkenes from carbon dioxide hydrogenation to gasoline and a preparation method of the catalyst. The catalyst takes gamma-Al2O3 as a carrier, the carrier is doped with three elements of Fe, Co and Na, and according to the weight of the carrier, the contents of the Fe, the Co and the Na are respectively 8.3wt.%, 1.7wt.% and 1.8-7.4 wt.%. The catalyst for the co-production of the low carbon alkenes from the carbon dioxide hydrogenation to the gasoline and the preparation method of the catalyst have the advantages that (1) selectivity of a by-product which is carbon monoxide can be greatly reduced by doping cobalt in an iron-base catalyst, the iron cobalt bimetallic metal has high selectivity of low-carbon olefin and gasoline distillate hydrocarbon under promotion of sodium, so while the FeCoNa / gamma-Al2O3 catalyst catalyzes the carbon dioxide hydrogenation to produce a gasoline cleaning product, the enane ratio of low-carbon hydrocarbons is greatly increased, and selectivity of methane and the carbon monoxide which are not ideal products is successfully inhibited; (2) the FeCoNa / gamma-Al2O3 catalyst has a high conversion rate of CO2; and (3) the space velocity of the reaction CO2 of the carbon dioxide hydrogenation catalyzed by the FeCoNa / gamma-Al2O3 catalyst is high.

The invention relates to a novel application of puerarin and derivates thereof in the pharmaceutical field. The puerarin and the derivates thereof have a COX-2-selective inhibition effect, are safe in use without toxic side effect, and have notable effectiveness. The puerarin and the derivates thereof can be used to prevent and cure osteoarthritis, rheumatic arthritis, rheumatoid arthritis, urarthritis, hepatitis, conjunctivis, myocarditis, secondary inflammations caused by tumor and diabetes, itai itai diseases caused by cold or trauma, and other difficult and baffling diseases.

The invention discloses a novel 2-hydroxyl chalcone compound (I), as well as pharmacy acceptable salt, preparation method, medical composition, and purpose thereof in preparing medicines for treating and / or preventing neurodegenerative diseases including but not limited to vascular dementia, Alzheimer's diseases, Parkinson's diseases, Huntington's diseases, dementia relevant to HIV, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, glaucoma and the like (As shown in the description.).

The invention provides a novel use of a ganoderic acid component with a structure shown in the general formula I as a 11 beta-hydroxysteroid dehydrogenase inhibitor. The ganoderic acid component as a 11 beta-hydroxysteroid dehydrogenase inhibitor with a novel structure has a certain selective inhibition effect on 11 beta-HSD1 and can be used for preparation of drugs for adjusting lipid metabolism and treating diabetes, adiposis and cardiovascular diseases.

The invention discloses a flotation separation method of high-sulfur and high-arsenic gold ore, and belongs to the technical field of mineral processing. The flotation separation method comprises thesteps of (1) grinding raw ore to the preset fineness; (2) performing shaking table sorting treatment on ground products so as to recycle natural and native gold dissociated from the raw ore; and (3) merging shaking table tailings, then performing flotation operation, adding water glass and macromolecular agents containing -OH and -O- groups as a combined inhibitor, adding copper sulfate as an activating agent, fully mixing, then adding a collecting agent and a foaming agent, and performing flotation separation so as to obtain gold concentrates. According to the flotation separation method of the high-sulfur and high-arsenic gold ore, gold is recycled by adopting a reselection-flotation combined technological process, so that the recycling of gold is strengthened; the macromolecular agentscontaining the -OH and -O- groups are added, so that the inhibiting effects on chlorite, steatite and other laminar silicate mineral gangue minerals are enhanced, efficient separation of gold carryingminerals and gangue minerals is realized, and the grade of the gold concentrates is guaranteed. The process has the advantages of operation simplicity and high adaptability to ore and can satisfy the requirements of industrial production.

The present invention discloses a T-cell immune response inhibitor. The T-cell immune response inhibitor supplied in the present invention comprises a targeted pathogen nucleic acid vaccine and said nucleic acid vaccine's expression protein antigen; or it comprises a targeted pathogen nucleic acid vaccine and said nucleic acid vaccine expression protein antigen's active polypeptide; or it comprises the inactivated pathogen and targeted pathogen nucleic acid vaccine. The T-cell immune response inhibitor in the present invention is able to stimulate the organism to produce the normal specific antibody immune response and to suppress a specific cell's immune response, in particular the Th1 immune response, thus it may be effectively applied to treatment of autoimmune diseases, organ transplants, allergies and control of T-cell levels.

The invention relates to a beneficiation method for mixed refractory tungsten ore. The beneficiation method comprises the following steps: (1) grinding crushed raw ore of scheelite and wolframite paragenic ore to obtain ore pulp; (2) when the pH value of the ore pulp is 7.0-9.0, an inhibitor, adding an activating agent lead nitrate and a collecting agent for mixed tungsten roughing, and respectively obtaining tungsten rough concentrate ore pulp and roughing tailing ore pulp; (3) performing mixed tungsten scavenging operation on the roughing tailing ore pulp twice to obtain tungsten scavenging tailings I; (4) carrying out weak magnetic iron removal operation on the tungsten rough concentrate ore pulp to respectively obtain a magnetic iron product and magnetic separation tailing ore pulp; (5) carrying out strong magnetic roughing and scavenging on the magnetic separation tailing ore pulp to respectively obtain a wolframite concentrate product and scavenging operation tailings; (6) performing dense dehydration on the scavenging operation tailings, and obtaining ore pulp with the concentration being 60%-70%; and (7) carrying out concentrated scheelite flotation operation on 60%-70% of ore pulp to respectively obtain scheelite concentrate and tungsten scavenging tailings II. The method provided by the invention effectively realizes effective separation and enrichment of wolframite and scheelite.

The invention discloses a calcium-containing or silicate-containing gangue mineral flotation depressant and a preparation method and application thereof. The flotation depressant is formed by polymerizing an inorganic polymer and metal ions. The preparation method of the flotation depressant comprises the steps that diatomaceous earth and a sodium hydroxide solution react under a high-temperatureand high-pressure condition to obtain the inorganic polymer, and then polymerization reaction is carried out on the inorganic polymer and metal salt to obtain the flotation depressant. The method is simple and low in cost, the prepared flotation depressant has extremely strong selective depressing effect on the calcium-containing and silicate-containing gangue mineral so that high-efficiency flotation separation of a tungsten-containing mineral from the gangue mineral can be realized; and the use amount of a chemical agent is small, the cost is low, and the flotation index is stable so that the depressant and the method can be widely applied to the great improvement of the concentrate grade and the recovery rate in the tungsten ore flotation process.

The invention discloses a water-soluble copper (II) complex as well as a synthesis method and an application thereof. The water-soluble copper (II) complex has the chemical formula being [Cu(L)(SO4)(HCl)], wherein L denotes N-(4-benzoic acid-2-diethylaminoethyl)-8-quinoline aldimine hydrochloride ligand; the complex belongs to the P-1 space group of the triclinic system, the cell parameters are shown as follows: alpha is equal to 95.262(5) angstrom, beta is equal to 98.450(5) angstrom and gamma is equal to 99.530(5) angstrom. The synthesis method of the complex comprises steps as follows: the ligand and copper sulfate pentahydrate are taken and subjected to a complexing reaction in a first polar solvent, and the complex is obtained. The applicant finds that the complex has a selective inhibition function on MGC80-3 and HeLa tumor cell beads and has lower toxicity to liver cells.

The invention discloses a collophanite reverse flotation depressing agent and an application thereof. The collophanite reverse flotation depressing agent is prepared by use of a method which comprises the steps of heating phosphoric acid to the range from 90 to 110 DEG C, continuously adding phosphorus pentoxide and stirring for dispersing, and after finishing adding, preserving heat and continuing stirring for 0.5-1.0 hour to obtain the collophanite reverse flotation depressing agent, wherein a mass ratio of the phosphoric acid to the phosphorus pentoxide is 1: 1 to 1: 4, the concentration of the phosphoric acid is that the mass percent content of P2O5 is 20-85wt%, the phosphorus pentoxide powder is the oxides of yellow phosphorus, and the mass percent content of P2O5 of the phosphorus pentoxide powder is more than 95wt%. The depressing agent has strong selective depression effect relative to single phosphoric acid or sulfuric acid, and thus is low in dosage in flotation, and meanwhile, the dosage of the phosphoric acid or the sulfuric acid also can be reduced. The collophanite reverse flotation depressing agent overcomes the shortcomings of calcium scaling and pipe blockage due to high dosage of the phosphoric acid or the sulfuric acid, and high flotation cost of a traditional process.

The present invention relates to a berberrubine derivative having superior antifungal activity, more particularly to a berberrubine derivative having inhibitory activity against chitin synthase, which participates in the synthesis of chitin and is essential in the growth of fungi, and having a potent antifungal activity against human pathogenic fungi.

The invention belongs to the technical field of medicine, and relates to a (N-1,2,3,4-tetrahydroisoquinolinyl)-feruloylagmatine compound, and a preparation method and application thereof. The structure is as shown in a formula I (the formula I is as shown in the description). The (N-1,2,3,4-tetrahydroisoquinolinyl)-feruloylagmatine compound provided by the invention has excellent butyrylcholine esterase inhibiting activity, remarkable Abeta1-42 aggregation inhibiting activity, anti-oxidation activity and high neuroprotective activity on PC12 cell injury induced by hydrogen peroxide in in-vitro experiments; and the (N-1,2,3,4-tetrahydroisoquinolinyl)-feruloylagmatine (I) compound is a multi-target-point inhibitor, further shows a good effect of treating alzheimer disease in in-vivo experiments, and has low toxicity and a good clinical application prospect.

The invention discloses a copper-based coordination polymer, a preparation method thereof and an application of the polymer serving as a gangue mineral inhibitor to copper-nickel sulfide ore flotation. Polyacrylic acid-carboxymethyl cellulose mixed anhydride and bivalent copper ions are coordinated and polymerized to obtain the copper-based coordination polymer. The copper-based coordination polymer can be effectively dispersed in solution and self-assembled to form colloidal particles loaded with strong negative charge on surfaces, so that the copper-based coordination polymer can be attachedto the surfaces of gangue minerals loaded with positive charged on the surfaces, and the gangue mineral is strongly hydrophilic. The copper-based coordination polymer is applied to copper-nickel sulfide ore flotation and has high selective inhibitory effects on the gangue minerals such as serpentines and quartz loaded with the positive charged on the surfaces, so that copper-nickel sulfide ores and the gangue minerals can be efficiently separated by flotation.